SOURCE: Nuvilex, Inc.

Nuvilex, Inc.

May 02, 2013 08:30 ET

Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity Than Competitors

NEW YORK, NY--(Marketwired - May 2, 2013) -  Nuvilex, Inc. (OTCQB: NVLX) has already produced impressive results from its two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer. Two key results pulled from the data of those trials, are that the median survival rate was higher than that of the current gold standard for the disease and better than those of other competitors' treatments when clinical trial reports are examined. Furthermore, the overall side-effect profile (toxicity) was much lower with Nuvilex's treatment than those of competitors' treatments.

Nuvilex's pancreatic cancer treatment uses the company's "Cell-in-a-Box" or living cell encapsulation technology along with the single anticancer drug ifosfamide. The encapsulated cells are capable of converting the ifosfamide into its cancer-killing form. Through two clinical trials, Nuvilex's treatment has performed admirably with results that included a median survival time and one-year survival rate that were doubled as compared to historical data for Gemzar, the only drug to date approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer.

Digging deeper into those survival rate results, a finer point on the data would be to simplify it down to real numbers. At the time Nuvilex's clinical trials were conducted, Gemzar's historical data gave patients a median survival time of 5.5 months; whereas, Nuvilex's treatment during the two clinical trials resulted in a median survival time of 11 months.

In January of this year, NASDAQ's Celgene Corp. reported the results for its treatment for advanced pancreatic cancer at the American Society of Clinical Oncology's (ASCO) Gastrointestinal Cancers Symposium in January. Celgene's treatment includes gemcitabine (Gemzar) in combination with their drug Abraxane, a nanoparticle albumin-bound formulation of paclitaxel (Taxol).

Continue reading this article at

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform that allows CEOs to tell their story through the press with Feature Articles, Research Reports, and CEO Interviews. At the same time, Stock House Group is building a library of Research for Investors to use that allows them to get more informed on small cap stocks. For more information visit Stock House Group at

Contact Information